Sugi Predict

Sugi Predict / Targets / FES

FES

Tyrosine-protein kinase Fes/Fps · P07332 · FES on Sugi Atlas →

48,368 patent compounds predicted against FES, 39,890 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Sunitinib Sunitinib (SCHEMBL8081) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL8082) 1.00 2/20
Linifanib Linifanib (SCHEMBL93804) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL93829) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL94020) 1.00 2/20
Tae-684 Tae-684 (SCHEMBL282775) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL18648) 0.92 2/20
Sunitinib Sunitinib (SCHEMBL55459) 0.84 2/20
SCHEMBL232936 SCHEMBL232936 0.79 2/20
SCHEMBL143584 SCHEMBL143584 0.78 2/20
SCHEMBL143543 SCHEMBL143543 0.77 2/20
SCHEMBL143185 SCHEMBL143185 0.75 2/20
SCHEMBL144887 SCHEMBL144887 0.74 2/20
SCHEMBL144383 SCHEMBL144383 0.74 2/20
SCHEMBL139873 SCHEMBL139873 0.72 2/20
SCHEMBL143316 SCHEMBL143316 0.71 2/20
SCHEMBL144905 SCHEMBL144905 0.71 2/20
SCHEMBL145888 SCHEMBL145888 0.71 2/20
SCHEMBL142711 SCHEMBL142711 0.70 2/20
SCHEMBL72322 SCHEMBL72322 0.69 2/20

Clinical trials — most relevant to FES by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer PHASE4RECRUITING
[18F]FES PET/CT in Endocrine Refractory Breast Cancer PHASE2COMPLETED
[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer PHASE2RECRUITING
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy PHASE2ACTIVE_NOT_RECRUITING
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia PHASE2COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms PHASE1/PHASE2RECRUITING
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer PHASE2COMPLETED
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy PHASE2ACTIVE_NOT_RECRUITING
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites PHASE2COMPLETED
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... PHASE1RECRUITING
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer nanCOMPLETED
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer nanUNKNOWN
MPN Childhood Registry nanRECRUITING
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer nanUNKNOWN
Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer nanACTIVE_NOT_RECRUITING
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells nanCOMPLETED
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies. nanCOMPLETED
Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FES binder may also engage these)

ProteinNameSimilarity
P16879 — 1.000 P16879 →
P14238 — 1.000 P14238 →
P00542 — 1.000 P00542 →
P00530 — 0.997 P00530 →
P00541 — 0.986 P00541 →
A1IGU3 — 0.981 A1IGU3 →
Q99JB8 — 0.981 Q99JB8 →
P70218 — 0.980 P70218 →
A1IGU4 — 0.980 A1IGU4 →
A1IGU5 — 0.980 A1IGU5 →
Q6ZT62 — 0.978 Q6ZT62 →
Q15027 — 0.978 Q15027 →
Q8C2K1 — 0.978 Q8C2K1 →
Q8CJ53 — 0.978 Q8CJ53 →
O15068 — 0.978 O15068 →
GRB7 Growth factor receptor-bound protein 7 0.978 landscape →
CDC42BPG Serine/threonine-protein kinase MRCK gamma 0.976 landscape →
Q99KF0 — 0.976 Q99KF0 →
Q8K045 — 0.976 Q8K045 →
Q64096 — 0.976 Q64096 →
Q9BXL6 — 0.975 Q9BXL6 →
Q63406 — 0.975 Q63406 →
Q5RCJ1 — 0.975 Q5RCJ1 →
Q8K2H4 — 0.975 Q8K2H4 →
Q8R5F8 — 0.975 Q8R5F8 →
Q9UKS6 — 0.975 Q9UKS6 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.974 landscape →
Q03160 — 0.974 Q03160 →
P55146 — 0.974 P55146 →
O94887 — 0.974 O94887 →